FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly is intervening in a lawsuit filed by a trade group representing compounding pharmacies, aiming to block the FDA's determination that the shortage of its GLP-1 medications, Mounjaro and ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide. The US ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Later in October, the FDA said it was reassessing its decision to ban compounding pharmacies from supplying cheaper versions of Eli Lilly’s weight loss and diabetes drugs. In December ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...